NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 20 04:00PM ET
0.3429
Dollar change
-0.0076
Percentage change
-2.17
%
IndexRUT P/E- EPS (ttm)-0.43 Insider Own16.97% Shs Outstand141.58M Perf Week-6.05%
Market Cap48.55M Forward P/E- EPS next Y-0.41 Insider Trans-0.67% Shs Float117.55M Perf Month-21.26%
Enterprise Value0.49M PEG- EPS next Q-0.16 Inst Own74.93% Short Float15.32% Perf Quarter-31.38%
Income-43.51M P/S179.81 EPS this Y23.30% Inst Trans-5.66% Short Ratio8.40 Perf Half Y-70.18%
Sales0.27M P/B1.32 EPS next Y30.09% ROA-41.81% Short Interest18.01M Perf YTD-59.95%
Book/sh0.26 P/C0.96 EPS next 5Y24.56% ROE-83.71% 52W Range0.29 - 10.62 Perf Year-92.90%
Cash/sh0.36 P/FCF- EPS past 3/5Y43.17% 26.57% ROIC-111.73% 52W High-96.77% Perf 3Y-68.83%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin-54.14% 52W Low16.24% Perf 5Y-99.20%
Dividend TTM- EV/Sales1.81 EPS Y/Y TTM78.99% Oper. Margin-40875.94% Volatility4.98% 4.16% Perf 10Y-
Dividend Ex-Date- Quick Ratio3.00 Sales Y/Y TTM- Profit Margin-16357.52% RSI (14)41.70 Recom2.25
Dividend Gr. 3/5Y- - Current Ratio3.00 EPS Q/Q77.50% SMA20-7.27% Beta1.87 Target Price3.17
Payout- Debt/Eq0.07 Sales Q/Q-100.00% SMA50-11.93% Rel Volume0.58 Prev Close0.35
Employees35 LT Debt/Eq0.06 EarningsMay 13 AMC SMA200-88.37% Avg Volume2.14M Price0.34
IPOMay 14, 2019 Option/ShortYes / Yes EPS/Sales Surpr.17.81% -100.00% Trades Volume1,237,924 Change-2.17%
Date Action Analyst Rating Change Price Target Change
Dec-23-24Downgrade William Blair Outperform → Mkt Perform
Dec-02-24Downgrade UBS Buy → Neutral $13 → $2
Nov-29-24Downgrade RBC Capital Mkts Outperform → Sector Perform $12 → $4
Jul-31-24Initiated William Blair Outperform
Mar-26-24Initiated RBC Capital Mkts Outperform $12
Feb-22-24Initiated Leerink Partners Outperform $12
Jan-04-22Downgrade Barclays Overweight → Equal Weight $44 → $7
Aug-27-21Downgrade Goldman Neutral → Sell $16 → $10
Jun-25-21Resumed Goldman Neutral $18
Oct-08-20Initiated Truist Buy $85
Jun-17-25 04:05PM
May-18-25 07:28AM
May-13-25 05:00PM
May-09-25 05:00PM
May-07-25 08:10AM
05:50PM Loading…
Apr-14-25 05:50PM
Apr-03-25 04:42PM
Mar-31-25 07:10AM
Mar-19-25 07:00AM
Feb-28-25 05:54AM
Feb-04-25 05:45AM
Jan-21-25 07:00AM
Jan-08-25 01:02PM
07:50AM
Jan-06-25 09:13AM
10:10AM Loading…
Jan-02-25 10:10AM
Dec-29-24 01:13PM
Dec-27-24 05:45AM
Dec-24-24 03:31PM
07:33AM
Dec-20-24 05:15PM
07:00AM
Dec-18-24 08:29PM
Nov-30-24 06:40AM
05:30AM
Nov-29-24 03:56PM
10:49AM
10:48AM
10:06AM
08:46AM
07:02AM Loading…
Nov-28-24 07:02AM
Nov-27-24 04:10PM
Nov-07-24 07:00AM
Nov-05-24 07:00AM
Oct-29-24 12:00PM
09:40AM
Oct-10-24 09:40AM
Sep-24-24 09:40AM
Sep-23-24 12:00PM
Sep-18-24 10:56AM
10:52AM
07:00AM
Sep-04-24 07:00AM
Aug-07-24 07:00AM
Jul-31-24 02:37PM
Jul-01-24 07:00AM
Jun-29-24 08:50PM
May-10-24 02:47PM
May-09-24 01:55PM
07:00AM
May-07-24 07:00AM
Apr-15-24 07:00AM
Apr-04-24 07:00AM
Mar-28-24 05:12PM
04:42PM
04:30PM
Mar-13-24 09:23AM
Mar-08-24 04:32AM
Mar-06-24 07:00AM
Feb-28-24 01:01PM
09:48AM
08:05AM
08:00AM
Feb-21-24 09:21AM
Feb-15-24 07:00AM
Jan-05-24 09:23AM
03:31AM
02:32AM
Jan-04-24 04:05PM
Jan-03-24 07:00AM
Nov-09-23 08:34AM
07:30AM
Nov-02-23 07:00AM
Nov-01-23 07:00AM
Oct-20-23 01:22PM
Sep-28-23 07:00AM
Sep-06-23 07:00AM
Aug-11-23 07:42AM
Aug-10-23 07:00AM
Jul-29-23 11:07AM
Jul-25-23 07:00AM
Jun-22-23 07:00AM
Jun-15-23 07:00AM
May-25-23 07:00AM
May-11-23 07:00AM
May-05-23 02:24PM
Apr-24-23 07:00AM
07:00AM
Mar-23-23 06:30AM
Mar-18-23 09:54AM
Mar-01-23 07:00AM
Feb-16-23 10:46AM
07:00AM
Feb-09-23 07:00AM
Jan-04-23 06:00AM
Nov-09-22 07:00AM
Oct-31-22 07:00AM
Oct-25-22 07:00AM
Oct-09-22 09:13AM
Oct-06-22 11:18AM
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Perfetti RiccardoChief Medical OfficerMar 04 '25Sale0.4410,3664,561890,409Mar 06 08:30 PM
Funtleyder Leslie D.See RemarksMar 04 '25Sale0.4414,5026,381390,459Mar 06 08:30 PM
Chinoporos ConstantineSee RemarksMar 04 '25Sale0.44447197271,436Mar 06 08:30 PM
Funtleyder Leslie D.See RemarksFeb 06 '25Sale0.6122,95014,000404,961Feb 07 08:30 PM
Perfetti RiccardoChief Medical OfficerFeb 06 '25Sale0.6186,07852,508900,775Feb 07 08:30 PM
Chinoporos ConstantineSee RemarksFeb 06 '25Sale0.6128,11717,151271,883Feb 07 08:30 PM
Funtleyder Leslie D.Chief Financial OfficerAug 22 '24Sale5.8313,53078,880277,911Aug 23 04:35 PM
Perfetti RiccardoChief Medical OfficerAug 22 '24Sale5.8322,681132,230986,853Aug 23 04:33 PM
Shendelman ShoshanaPresident and CEOAug 13 '24Sale6.18357,4232,208,8744,810,430Aug 14 07:01 PM
Shendelman ShoshanaPresident and CEOAug 12 '24Sale5.98300,0001,794,0005,167,853Aug 14 07:01 PM
Shendelman ShoshanaPresident and CEOAug 14 '24Sale5.93119,591709,1754,690,839Aug 14 07:01 PM
Shendelman ShoshanaOfficerAug 12 '24Proposed Sale6.211,000,0006,210,000Aug 09 08:43 PM